Edinburgh Research Explorer

Correction: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Research output: Contribution to journalArticle

Standard

Correction: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. / Hortobagyi, G N; Stemmer, S M; Burris, H A; Yap, Y S; Sonke, G S; Paluch-Shimon, S; Campone, M; Petrakova, K; Blackwell, K L; Winer, E P; Janni, W; Verma, S; Conte, P; Arteaga, C L; Cameron, D A; Mondal, S; Su, F; Miller, M; Elmeliegy, M; Germa, C; O'Shaughnessy, J.

In: Annals of oncology, 13.08.2019.

Research output: Contribution to journalArticle

Harvard

Hortobagyi, GN, Stemmer, SM, Burris, HA, Yap, YS, Sonke, GS, Paluch-Shimon, S, Campone, M, Petrakova, K, Blackwell, KL, Winer, EP, Janni, W, Verma, S, Conte, P, Arteaga, CL, Cameron, DA, Mondal, S, Su, F, Miller, M, Elmeliegy, M, Germa, C & O'Shaughnessy, J 2019, 'Correction: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer', Annals of oncology. https://doi.org/10.1093/annonc/mdz215

APA

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., ... O'Shaughnessy, J. (2019). Correction: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of oncology. https://doi.org/10.1093/annonc/mdz215

Vancouver

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S et al. Correction: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of oncology. 2019 Aug 13. https://doi.org/10.1093/annonc/mdz215

Author

Hortobagyi, G N ; Stemmer, S M ; Burris, H A ; Yap, Y S ; Sonke, G S ; Paluch-Shimon, S ; Campone, M ; Petrakova, K ; Blackwell, K L ; Winer, E P ; Janni, W ; Verma, S ; Conte, P ; Arteaga, C L ; Cameron, D A ; Mondal, S ; Su, F ; Miller, M ; Elmeliegy, M ; Germa, C ; O'Shaughnessy, J. / Correction: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. In: Annals of oncology. 2019.